Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03865992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

StatusActive, Not Recruiting
PhaseNot applicable
Started2019-03-04
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Sep 8, 2026 → Aug 4, 2027
See other at-risk trials from City of Hope Medical Center

Amendment history

2026-09-29
Primary completion pushed: 2026-09-08 → 2027-08-04
Completion pushed: 2026-09-08 → 2027-08-04
2025-11-06
Study Status v14
Primary completion date2025-10-17→2026-09-08
Completion date2025-10-17→2026-09-08
2025-02-04
Study Status v13
Primary completion date2024-12-31→2025-10-17
Completion date2024-12-31→2025-10-17
2024-01-29
Study Status v12
Primary completion date2023-12-31→2024-12-31
Completion date2023-12-31→2024-12-31
2023-09-07
Study Status v11
Primary completion date2023-07-31→2023-12-31
Completion date2023-07-31→2023-12-31
Show 10 earlier versions
2022-09-14
Study Status v10
Primary completion date2022-07-31→2023-07-31
Completion date2022-07-31→2023-07-31
2021-09-13
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v9
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 40→confirmed 42
Study sitesdetails revised at 4 of 4 sites
2020-09-08
Study Status, Contacts/Locations v8
Primary completion date2020-07-31→2022-07-31
Completion date2020-07-31→2022-07-31
Study sitesdetails revised at 3 of 4 sites
2020-04-28
Study Status v7
Re-verified, no change to tracked fields
2019-08-30
Study Status v6
Primary completion date2019-07-31→2020-07-31
2019-04-09
Study Status v5
Start dateestimated 2019-03-28→confirmed 2019-03-04
2019-04-01
Study Status, Outcome Measures v4
Primary endpoints2 entries, revised
FeasibilityChanges in aromatase inhibitor-induced symptoms and overall wellbeing in postmenopausal women on aromatase inhibitor therapy
2019-03-29
Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility v3
InterventionsCurcumin (Dietary Supplement), Placebo (Other)→Curcumin (Dietary Supplement), Nanoemulsion (Other), Placebo (Other), Quality-of-Life Assessment (Other), Questionnaire (Behavioral)
Secondary endpoints5 to 3 entries
ChangeIncidence inof Briefadverse Pain Inventory (BPI)events Change in DisabilitiesFACT-ES of the Arm, Shoulder and Hand (DASH)score Change in GeriatricDASH Assessment Grip strength Diet and Nutrition Assessmentscore
Primary endpoints1 to 2 entries
ChangesChange in FunctionalBrief AssessmentPain of Cancer Therapy-Endocrine SymptomsInventory (FACT-ESBPI) pain score Feasibility
Study description+6 characters
[...] ata regarding function in women with AI induced arthropathy (IA) by monitoring grip strength at 0 and 3 montsmonths of NEC versus placebo IV. To conduct exploratory analyses o [...]
2019-03-11
Not Yet Recruiting→Recruiting Study Status, Eligibility, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 4 of 4 sites
2019-03-06
Study Status, Conditions v1
Re-verified, no change to tracked fields
2019-03-05
Original filing
This phase I trial studies how well curcumin works in reducing joint pain in patients who are breast cancer survivors and have joint disease caused by treatment with aromatase inhibitors. Curcumin is an ingredient of turmeric, a plant in the ginger family, which is commonly used in curries and South Asian and Middle Eastern cooking, and may decrease joint pain in patients with arthritis from other conditions (such as osteoarthritis and rheumatoid arthritis).
Trial Details
NCT Number NCT03865992
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer, Joint Pain
Enrollment 42 participants
Start Date 2019-03-04
Primary Completion 2027-08-04 (estimated)
Study Completion 2027-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-09-28